Zuranolone Market

The market for Zuranolone was estimated at $116 million in 2025; it is anticipated to increase to $252 million by 2030, with projections indicating growth to around $546 million by 2035.

Report ID:DS1802008

Author:Debadatta Patel - Senior Consultant

Published Date:January 2025

Datatree

Life Science

Pharmaceutical

Zuranolone

Customization Available

Zuranolone - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Zuranolone Market Outlook

Revenue, 2025

$116M

Forecast, 2035

$545M

CAGR, 2026 - 2035

16.7%

The Zuranolone industry revenue is expected to be around $116.5 million in 2026 and expected to showcase growth with 16.7% CAGR between 2026 and 2035. A position of dominance in the treatment of central nervous system disorders is being established by Zuranolone, as there is considerable unmet need in cases of postpartum depression and major depressive disorder. The treatment of postpartum depression and major depression accounts for 94.4% of revenues generated from CNS disorder treatments. Zuranolones 30 mg dose has been the main driver of sales so far this year, bringing in $53.45 million in revenue for the industry by 2025. This is a sign of the strong support among doctors for Zuranolones treatment approach. This method involves taking a low dose orally for a short period of time. The trend is being driven by factors including growing evidence of rapid symptom relief for patients with MDD and PPD, greater awareness of mental health issues, regulatory developments, and an insurance industry that is increasingly willing to cover treatments that cut hospitalisation rates and improve patients quality of life.

This orally administered neuroactive steroid and a GABA A receptor positive allosteric modulator has been engineered to provide fast antidepressant effects following the intake of a standard short once daily treatment of 14 days. This therefore provides an alternative to traditional monoaminergic oral antidepressants. Zuranolone exhibits a number of notable qualities including the swift alleviation of depression, its administration taking place at home, and a mechanism of action that involves the modulation of GABA. As such, it appears to hold significant promise for the treatment of postpartum depression and major depression where rapid recovery is a priority. Clinical trials of Zuranolone are not only limited to the treatment of PPAN and depression but are also being conducted in other central nervous system disorders. The trials focus on 3 main factors: optimal dosing, the drug being given in combination with other antidepressants, and giving patients who live in different countries access to the treatment. Growing demand for antidepressants is driven by the increasing trend of screening for postpartum depression and the growing recognition of the fact that some forms of depression do not only respond to standard treatment. Another driver is the change in clinical practice guidelines for medications that affect GABA. Furthermore, Zuranolone is being used in tele psychiatry and in the community health care sector which tends towards giving patients medication that is effective, works quickly and is taken orally for a limited period.

Zuranolone market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Zuranolone Market Outlook

Market Key Insights

The anticipated growth rate for the Zuranolone market will reach $546 million by 2035 from an estimated 2025 value of $116.5 million. The compound annual growth rate of the company is 16.7 % in this case, a rise in the need for Zuranolone as an MDD treatment is the reason, Zuranolone as a PPD therapy is also on the rise and so is Zuranolone for GAD.
The market for neurological treatments is highly concentrated, dominated by three leading pharmaceutical companies. One of these companies is Sage Therapeutics, which currently enjoys the biggest market share.
The United States and Germany are leading markets in the global Zuranolone market and will grow at a compound annual rate of 16% to 23.4% from 2025 to 2030.
The fastest rates of expansion are predicted for emerging markets such as Brazil, India and South Africa, with a compound annual growth rate ranging from 12.5% to 17.4% .
The investment appeal of the Zuranolone market is set to be improved by the shift to personalized medicine amongst other factors. The proposed changes are envisioned to foster a beneficial cycle that in turn fuels growth and should bring in approximately $15 million by the years 2030 and 2026.
Over the period 2025 to 2035 the market for Zuranolone will increase by $429 million. This growth in the market will largely be due to the Homecare & Mental Health Centers Application segment.
Research in neuroscience coupled with growing mental health awareness will be a factor in a 368% increase in the market for Zuranolone between 2035 and 2025.

Zuranolone - Country Share Analysis

Opportunities in the Zuranolone

In the United States, there is also a growing concern about womens mental health plus limited availability of successful treatment for postpartum depression. Zuranolone, a fast acting antidepressant and a neurosteroid that is orally administered, can reduce readmission of patients and lead to improved health of mothers after delivery by short duration dosing. The highest demand is anticipated for 20 mg and 25 mg formulations. The 25 mg variant is predicted to experience an 18.5% Compound Annual Growth Rate . The 20 mg option will be valued at $25.04 million in 2025, then $48.84 million by 2030.

Growth Opportunities in North America and Asia-Pacific

A rapid acting orally administered antidepressant such as Zuranolone is likely to be especially useful in the immediate term for treating postnatal depression in North America. This is due to a strong infrastructure being in place for fast access to treatment. This infrastructure includes established screening procedures, payers that are ready to provide coverage, and high levels of public awareness about perinatal mental health. This patient population suffering from treatment resistant depression or major depressive disorder could benefit from a CNS active drug, since the marketplace for CNS therapeutics is mature and doctors are well versed in the mechanisms of both GABA receptor modulators and neurosteroid activity. Key opportunities include the marketing of Zuranolone as an initial treatment for short periods of time in women who are severely depressed after giving birth in hospitals and other medical centres that offer obstetric care and psychiatric treatment. Another key opportunity exists in the prescribing of Zuranolone in patients who have depression that does not only respond to other treatments. Pills and other intravenous treatments in the pipeline for depression drive competition. As such, treatments must differentiate by highlighting their rapid onset of action, capacity to promote recovery and ease of use through oral dosing compared to intravenous treatments. The region has a number of factors which drive growth in the field. These factors include a relatively straightforward process for regulatory approvals, the presence of active bodies which set clinical practice guidelines, a strong voice for mental health advocacy and a comprehensive infrastructure for gathering data from real world usage. These factors allow for the implementation of premium pricing, for the negotiation of outcomes based contracts and to expand the labels of treatments for depression.

Across the Asia Pacific, the major depressive disorder holds considerable potential for Zuranolone sales, due to high untreated patient numbers, an increasingly stressful urban environment and a reduction in the stigma of mental illness. Furthermore, there is a rising demand for the drug in Japan, South Korea and Australia to treat postnatal depression. The company plans to focus on multiple aspects in order to capitalise on the Zuranolone market. This involves premium branding in those developed countries within the region and it also involves tailoring the dosing regimen. Additionally, the firm will have to supply data regarding the cost of medication in those middle income countries to ensure that the medicine is included in formularies for depression. In this competitive market, where cheaper generic medicines and regional antidepressant brands dominate, the importance of positioning Zuranolone as a distinct GABA receptor modulator and neurosteroid that possesses rapid acting antidepressant properties cannot be overstated. This is particularly relevant as it has the potential to reduce hospital stays and shorten the time to achieve a response. Key drivers of this market in the region are increased insurance coverage, a growing government commitment to mental health, the construction of psychiatric facilities and growing links between local medical experts and the company. These factors will help to bring the product to market, gain price approval and increase the market size in the region over time for the treatment of depression.

Market Dynamics and Supply Chain

Driver: Rising Mental Health Awareness, and Surge in Healthcare Expenditure

The growing focus in society towards health has also brought attention to issues such as depression and anxiety in a significant way these days. This heightened awareness plays a role in driving the market expansion of Zuranolone given its primary use, for addressing depressive disorders. With the increase in global spending for healthcare services there is also a growing trend towards allocating resources to the research and procurement of advanced pharmaceuticals, like Zuranolone. The readiness of governments and healthcare institutions to support high quality medications also serves as a factor propelling the market forward.

Recent advancements in the field of neuroscience are also revealing possibilities for medications such as Zuranolone that regulate neurotransmitter functions to achieve their medicinal benefits. The ongoing scientific developments are also promoting usage and subsequently driving expansion, in the market.

Restraint: Increasing Competition from Alternative Treatments

There is competition for Zuranolone as it competes with several other medications on the market for depression and anxiety treatment that are well established and FDA approved which patients and healthcare experts tend to choose initially over newer options like Zuranolone might restrict its market growth due to the increasing favorability towards psychotherapy and lifestyle changes as safer alternatives, among some providers and patients.

Opportunity: Expansion of Zuranolone-based major depressive disorder therapy in outpatient psychiatric clinics across Europe and Growth of Zuranolone 25 mg and 30 mg CNS therapeutics in Asia-Pacific urban populations

Growing pressure on European psychiatric facilities due to the increasing incidence of major depressive disorder makes outpatient clinics good settings for the administration of Zuranolone. This neuroactive steroid functions rapidly through the mouth and acts on the brain. It can lead to a quicker recovery and less follow up visits in comparison to standard antidepressants and can allow patients to leave the hospital sooner. Partnerships between the pharmaceutical industry and healthcare providers, along with digital therapeutics, can help ensure compliance and keep track of treatment. By 2030, Europe's therapy market for major depressive disorder is expected to be driven by a product with a dosage strength of 30 milligrams which, as of 2025, was already earning $53.45 million globally. By 2026, this will have a growth rate of 16.46%.

Growing urban populations, increased healthcare spending and lower social stigma in the Asia Pacific region have raised demand for central nervous system treatments, which will benefit the product Zuranolone. Japan, Australia and South Korea are focusing their health services on fast acting, innovative kinds of antidepressant medication which decrease the effect of depression and the loss of productivity the condition causes. By 2030, the projected global sales of the 25mg and 30mg doses, which target working age urban populations, are forecast to exceed $200 million. The 25mg formulation is predicted to increase from $37.96 million in 2025 to $88.71 million by the same year. The Asia Pacific region is expected to be the most rapidly expanding market for this of treatment.

Challenge: Potential Side Effects and Safety Concerns

Like medications, in the pharmaceutical field doles out potential adverse reactions and safety worries that might hinder its market expansion prospects. The medication may induce feelings of dizziness and sleepiness among patients which could diminish its appeal to some individuals.

Supply Chain Landscape

Zuranolone API Manufacturing

Sage Therapeutics Shionogi & Co. Ltd WuXi AppTec

Neuroactive Steroid Formulation

Sage Therapeutics Catalent Pharma Solutions Thermo Fisher Scientific

Global Pharma Distribution

McKesson Corporation Cardinal Health AmerisourceBergen

Therapeutic End Use

Major depressive disorder postpartum depression GABA receptor modulator therapy

Zuranolone API Manufacturing

Sage Therapeutics Shionogi & Co. Ltd WuXi AppTec

Neuroactive Steroid Formulation

Sage Therapeutics Catalent Pharma Solutions Thermo Fisher Scientific

Global Pharma Distribution

McKesson Corporation Cardinal Health AmerisourceBergen

Therapeutic End Use

Major depressive disorder postpartum depression GABA receptor modulator therapy

Zuranolone - Supply Chain

Use Cases of Zuranolone in for Major Depressive Disorder (MDD) Treatment & for Generalized Anxiety Disorder (GAD)

ZURANOLONE for Major Depressive Disorder (MDD) Treatment : An oral neuroactive steroid called Zuranolone is mainly used to treat depressive disorder due to its fast acting and long lasting effects. Major companies such as Sage Therapeutics and Biogen have shown interest, in Zuranolone by collaborating on its worldwide advancement and market release.

ZURANOLONE for Postpartum Depression (PPD) Therapy : Zuranolone also plays a role in treating postpartum depression by standing out for its ability to alleviate symptoms within days instead of weeks like traditional antidepressants do. Providing quicker relief for new mothers in need of support during this challenging time period of their lives. The prominent companies in the market such, as Sage Therapeutics and Biogen are actively involved in researching and exploring the uses of Zuranolone in postpartum depression treatment.

ZURANOLONE for Generalized Anxiety Disorder (GAD) : Zuranolone also holds potential in treating anxiety disorder offering a different approach to therapy for individuals who do not only react positively to standard GAD medications. The rapid onset of effects and minimal side effects of Zuranolone elevate its value proposition, in the psychiatric medication sector.

Recent Developments

SAGE 217 or Zuranolone has been causing quite a stir in the field lately for its promising applications in treating various mental health conditions like major depressive disorder and postpartum depression . This groundbreaking development, by Sage Therapeutics introduces a perspective into the enduring mental health medication market.

December 2024 : Sage Therapeutics broadened its marketing efforts for Zuranolone to connect with an audience of potential patients.

October 2024 : Approval for the use of Zuranolone has been granted in countries such as Canada and Australia. This expansion opens up markets and opportunities, for increased sales.

September 2024 : Clinical studies have demonstrated that Zuranolone has proven effective in alleviating symptoms among individuals with depression. This has bolstered its position, within the market for health medications.

Impact of Industry Transitions on the Zuranolone Market

As a core segment of the Pharmaceutical industry, the Zuranolone market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Personalized Medicine and Increased Investment in Mental Health Research have redefined priorities across the Pharmaceutical sector, influencing how the Zuranolone market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Shift Towards Personalized Medicine

Personalised treatment approaches are being driven by the trend of Zuranolone moving towards targeted medical care. This has brought about a change from a market where products were central to one where data drives precision care. As a result, the markets attractiveness to investors has been increased. With the integration of biomarkers and advanced analytical tools along with data from real world studies, Zuranolone offers a novel treatment solution in psychiatry which is precise and for depression. This transition allows for more effective treatments, reduces unwanted side effects, and allocates healthcare resources in a more efficient way across all brain disorder therapies, in turn winning support from both insurers and doctors. Between 2026 and 2030, Zuranolone in advanced neuropsychiatric care is expected to benefit from a self sustaining growth cycle as biomarker driven treatments are scaled up. This will add USD 15 million in market value and strengthen the firms position in the long term.

Increased Investment in Mental Health Research

Research into the field of mental health has seen significant growth in investment.